Zim Laboratories (NSE:ZIMLAB) Cyclically Adjusted Revenue per Share: ₹79.77 (As of Mar. 2026)


NSE:ZIMLAB Zim Laboratories Ltd NSE:ZIMLAB
78 GF Score
Price ₹122.01
GF Value ₹102.82
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Zim Laboratories Cyclically Adjusted Revenue per Share?

Zim Laboratories NSE:ZIMLAB -2.00% 78 Cyclically Adjusted Revenue per Share is ₹79.77 as of Mar. 2026. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 78/100 and a GF Value™ of ₹102.82 (Modestly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zim Laboratories's adjusted revenue per share data for the fiscal year that ended in Mar. 2026 was ₹73.509. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹79.77 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Zim Laboratories's average Cyclically Adjusted Revenue Growth Rate was 2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-03), Zim Laboratories's current stock price is ₹ 122.01. Zim Laboratories's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Mar. 2026 was ₹79.77. Zim Laboratories's Cyclically Adjusted PS Ratio of today is 1.53.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Zim Laboratories was 1.60. The lowest was 0.84. And the median was 1.30.


Zim Laboratories  (NSE:ZIMLAB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zim Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=122.01/79.77
=1.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Zim Laboratories was 1.60. The lowest was 0.84. And the median was 1.30.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zim Laboratories Cyclically Adjusted Revenue per Share Related Terms


Zim Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Zim Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zim Laboratories Cyclically Adjusted Revenue per Share Chart

Zim Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 75.88 77.62 79.77

Zim Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 77.62 0.00 0.00 0.00 79.77

NSE:ZIMLAB vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zim Laboratories Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zim Laboratories's Cyclically Adjusted PS Ratio falls into.


NSE:ZIMLAB
78GF Score
Zim Laboratories Ltd NSE:ZIMLAB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zim Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zim Laboratories's adjusted Revenue per Share data for the fiscal year that ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=73.509/164.2724*164.2724
=73.509

Current CPI (Mar. 2026) = 164.2724.

Zim Laboratories Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201703 47.187 105.196 73.686
201803 54.657 109.786 81.783
201903 67.024 118.202 93.147
202003 53.648 124.705 70.670
202103 59.972 131.771 74.764
202203 67.366 138.822 79.716
202303 79.779 146.865 89.235
202403 72.962 153.035 78.320
202503 74.475 157.552 77.652
202603 73.509 164.272 73.509

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹79.77 mean?
Zim Laboratories (NSE:ZIMLAB) has a Cyclically Adjusted Revenue per Share of ₹79.77 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zim Laboratories and its competitors.
Is Zim Laboratories' Cyclically Adjusted Revenue per Share too high?
Zim Laboratories' current Cyclically Adjusted Revenue per Share is ₹79.77. Overall, Zim Laboratories has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zim Laboratories' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Zim Laboratories' Cyclically Adjusted Revenue per Share of ₹79.77 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zim Laboratories and its competitors. Zim Laboratories's current Cyclically Adjusted Revenue per Share is ₹79.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹102.82, compared to a current price of ₹122.01 — trading 18.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹79.77. Zim Laboratories' overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current Cyclically Adjusted Revenue per Share is ₹79.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued. The current stock price of ₹122.01 is trading 18.7% above its estimated GF Value™ of ₹102.82. GuruFocus considers Zim Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:ZIMLAB:

  • Cyclically Adjusted Revenue per Share: ₹79.77
  • GF Value™: ₹102.82 vs. price of ₹122.01 (18.7% above fair value)
  • GF Score™: 78/100 with 8 warning signs

No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zim Laboratories Business Description

Other Exchanges 541400:India
Address Nelson Square, Chhindwara Road, Sadoday Gyan, Ground Floor, Opposite NADT, Nagpur, MH, IND, 440 013
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
78GF Score

Get the complete analysis for NSE:ZIMLAB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹122.01
Price
₹102.82
GF Value